Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children

Drug, Healthcare and Patient Safety

Volumn 6, Issue 1, 2014, Pages 15-20

  Di Pierro, Francesco ^a   Colombo, Maria ^b   Zanvit, Alberto ^c   Risso, Paolo ^d   Rottoli, Amilcare S ^e  

^a Scientific Department   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c Italian Stomatological Institute   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e Department of Anesthesia and Resuscitation   (Italy)

Author keywords

Antibiotic therapy; Bactoblis; Blis K12; Pediatric trial; S. pyogenes

Indexed keywords

BACTOBLIS; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTICLE; BACTERIAL STRAIN; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; STREPTOCOCCAL PHARYNGITIS; STREPTOCOCCUS SALIVARIUS; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL PHARYNGITIS;

EID: 84894327404     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/dhps.s59665     Document Type: Article

References (18)

1. Tagg JR. Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes acteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Indian J Med. 2004;119 Supp l:13-16.
2. Hyink O, Wescombe PA, Upton M, Ragland N, Burton J P, Tagg. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol. 2007;73(4):1107-1113.
3. Sharma S, Verma KK. Skin and soft tissue infection. Indian J Pediatr. 2001;68 Suppl 3:S46-S50.
4. Wescombe PA, Burton J P, Cadieux PA, et al. Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivarius. Antonie Van Leeuwenhoek. 2006;90(3):269-280.
5. Wescombe PA, Hale JD, Heng NC, Tagg JR. Developing oral probi-otics from Streptococcus salivarius. Future Microbiol. 2012;7(12): 1355-1371.
6. Van Zon A, Van der Heijden GJ, Van Dongen TM, Burton MJ, Schilder AG. Antibiotics for otitis media with effusion in children. Cochrane Database Syst Rev. 2012;9: CD009163.
7. Power DA, Burton J P, Chilcott CN, Dawes PJ, Tagg JR. Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis. 2008;27(12): 1261-1263.
8. Horz H P, Meinelt A, Houben B, Conrads G. Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral Microbiol Immunol. 2007;22(2):126-130.
9. Burton J P, Wescombe PA, Moore CJ, Chilcott CN, Tagg JR. Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl Environ Microbiol. 2006;72(4):3050-3053.
10. Burton J P, Cowley S, Simon RR, McKinney J, Wescombe PA, Tagg JR. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol. 2011;49(9):2356-2364.
11. Di Pierro F, Adami T, Rapacioli G, Giardini N, Streitberger C. Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin Biol Ther. 2013;13(3): 339-343.
12. Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991-997.
13. Burton J P, Chilcott CN, Tagg JR. The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics. Oral Dis. 2005;11 Suppl 1:29-31.
14. Burton J P, Chilcott CN, Moore CJ, Speiser G, Tagg JR. A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol. 2006;100(4):754-764.
15. Ishijima SA, Hayama K, Burton J P, et al. Effect of Streptococcus salivarius K12 on the in vitro growth of Candida albicans and its protective effect in an oral candidiasis model. Appl Environ Microbiol. 2012;78(7):2190-2199.
16. Murray RC, Chennupati SK. Chronic streptococcal and non- streptococcal pharyngitis. Infect Disord Drug Targets. 2012;12(4):281-285.
17. Bonsignori F, Chiappini E, De Martino M. The infections of the upper respiratory tract in children. Int J Immunopathol Pharmacol. 2010;23(Suppl 1):16-19.
18. Singh V P, Sharma J, Babu S, Rizwanulla MT, Singla A. Role of probiotics in health and disease: a review. J Pak Med Assoc. 2013;63(2): 253-257.